Key facts
- TransCode Therapeutics completed its Phase 1a clinical trial for TTX-MC138.
- The trial reported no dose-limiting toxicities.
- Durable disease stabilization was observed in metastatic cancer patients.
- The company is advancing to Phase 2 development.
- The Phase 2 trial will focus on ctDNA-positive cancers.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has successfully completed its Phase 1a clinical trial for its drug candidate TTX-MC138. The trial results indicated no dose-limiting toxicities and demonstrated durable disease stabilization in patients with metastatic cancer. Following these positive outcomes, TransCode Therapeutics is progressing to Phase 2 development. The next phase will specifically target patients with ctDNA-positive cancers, utilizing the company's next-generation RNA therapeutics.